BAY1082439

BAY1082439 is an orally bioavailable, selective small molecule inhibitor of class I phosphoinositide 3‑kinase (PI3K) alpha, beta, and delta isoforms. It was developed by Bayer for the potential treatment of cancer. The drug acts by selectively inhibiting PI3K alpha (including mutated forms such as PIK3CA), PI3K beta, and PI3K delta within the PI3K/Akt/mTOR signaling pathway. This inhibition can result in tumor cell apoptosis and growth inhibition in tumors that express PI3K or are driven by PTEN loss. By targeting these specific isoforms rather than all class I PI3Ks (pan-inhibition), it may offer improved efficacy with reduced toxicity compared to less selective inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is common in solid tumors and contributes to increased tumor cell growth, survival, and resistance to therapy[1][2][5][6]. Preclinical studies have shown that BAY1082439 is effective against PTEN-null prostate cancer models and can prevent epithelial-mesenchymal transition (EMT) as well as block B-cell–mediated tumor-promoting signals from the microenvironment[6][8].